Breadcrumbs NavigationHome > News & Publications > News and Communications > News > First-in-Class Compound Proves Safe, Tolerable in Preventing Blood Clots
First-in-Class Compound Proves Safe, Tolerable in Preventing Blood Clots
A new drug derived from magnolia trees appears to be able to uncouple two important functions of thrombin in blood clot formation and may offer a way to better control the potentially dangerous complications of bleeding and clot formation during procedures to open blocked coronary arteries, say researchers at the Duke Clinical Research Institute (DCRI).
Results of the Phase II study of the drug known as SCH 530348 appear online in the journal The Lancet and will appear in the publication's Mar. 14 issue. An international Phase III study is already under way.
Thrombin is a protein in the blood that performs two key functions in clot formation: It activates platelets, particles that clump together to form the scaffolding of a clot, and it helps produce fibrin, a protein necessary in repairing damaged tissue.
"One of the intriguing things about this new investigational compound is that it blocks the thrombin receptor that activates platelet formation yet preserves the beneficial activity of fibrin formation," said Richard Becker, MD, a cardiologist at DCRI and the lead author of the study.
"And the data to date indicate the compound does this even when patients are taking aspirin and clopidogrel."
Blood clots are a big issue for patients facing percutaneous coronary intervention (PCI), the process of clearing clogged arteries with a balloon and then propping them open with stents. Patients who undergo PCI are usually prescribed anti-clotting agents like aspirin or clopidgrel (Plavix).
Becker said while those drugs are effective, they can sometimes lead to bleeding, and with current therapy, the rate of additional cardiovascular events remains quite high. "So there is a very aggressive search going on for better and safer agents," he said.
In the current study, researchers randomly assigned 1,030 patients who were 45 years or older and scheduled to undergo non-urgent PCI or angiography with planned PCI to a group that would receive one of three escalating doses of SCH 530348 (10 mg, 20 mg, or 40 mg), or to a control group that took a placebo.
Both researchers and patients were unaware as to who was taking which drug.
Aspirin and clopidogrel were not prescribed as part of the study -- investigators followed standard practice at each study site and found that 95 percent of the patients were given both aspirin and clopidogrel.
Two hundred and twenty-seven patients were assigned to placebo; 773 took the experimental drug. Researchers measured responses across all four groups with special focus on the primary clinical endpoint, which was the amount of bleeding according to the thrombolysis in myocardial infarction (TIMI) scale.
They found that SCH 530348 was generally tolerable at all dosing levels and did not increase bleeding, even when taken along with aspirin and clopidogrel.
Bleeding occurred in two percent of 129, three percent of 120, and four percent of 173 patients in the 10 mg, 20 mg, and 40 mg drug groups, respectively; compared with three percent of the 151 patients in the placebo group (p = .5786).
Patients were also randomized to a daily maintenance dose of the drug (.5 mg, 1 mg, or 2.5 mg). Investigators found that bleeding occurred in two percent of 136, four percent of 139 and three percent of 138 patients in those groups, respectively, compared with two percent in the placebo group (p = .7561).
"The uncoupling of benefit and bleeding risk among patients with acute coronary syndromes is an important objective in drug development," Becker said. "We will need to see if Phase III clinical trials can confirm these findings."
Co-authors from Duke on the study include senior author Robert Harrington, Karen Pieper and Diane Joseph. Additional co-authors include David Moliterno and Khaled Ziada, from the University of Kentucky; Lisa Jennings, from the University of Tennessee Health Sciences Center; Alan Niederman, from The Jim Moran Heart and Vascular Research Institute; Frans Van de Werf, from University Hospitals Leuven, Belgium; and Jinglan Pei, Gail Berman, John Strony and Enrico Veltri, from Schering-Plough.
Pieper, Joseph, Ziada and Joseph report no interest or support from Schering-Plough. All other authors report research support, consulting fees or stock in the company.
Schering-Plough funded the study.
About This Article
Published: Mar. 12, 2009
Updated: Mar. 12, 2009
Reporters & producers can visit Duke Medicine News and Communications for contact information.